Severe weather cited for discontinued manufacturing

Article

PixelOptics will discontinue the atLast! Line of enhanced multifocal lenses, due to winter flood damage at the company?s primary manufacturing site in Thailand, the company announced.

Roanoke, VA-PixelOptics will discontinue the atLast! Line of enhanced multifocal lenses, due to winter flood damage at the company’s primary manufacturing site in Thailand, the company announced. The line was launched worldwide in October 2008.

“It is with deep regret that we have made the decision to discontinue production on our family of atLast! products,” said Brett Craig, PixelOptics president and CEO. “Despite significant efforts to resolve supply issues following floods at our Thailand factory, it has become apparent that production cannot be restored in a timely manner to meet current demand. This decision was not taken lightly and we remain committed to supporting our customers through this period of transition.”

The company’s emPower! Line, manufactured in Japan, is not affected. The company said its U.S. rollout for emPower! is expected to continue and would be followed by a series of European launches throughout the year.

Although the company said the loss of its atLast line is unfortunate, it provides the company the ability to focus its full effort on emPower!

For more articles in this issue of InDispensable, click here.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.